Document Detail


Global Forum on TB Vaccine Research and Development. World Health Organization, June 7-8 2001, Geneva.
MedLine Citation:
PMID:  11800588     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The TB community now envisions a turning point in the development of improved TB vaccines for both high and low incidence countries. With a number of viable TB vaccine candidates now available for testing, the investigation of safety and immunogenicity in human clinical trials is seen as the driving force for the future development of effective vaccines for the prevention of tuberculosis.
Authors:
M J Brennan; U Fruth
Related Documents :
3877008 - A case-control study of bcg and childhood tuberculosis in cali, colombia.
23733038 - Effectiveness of seasonal influenza vaccine against clinically diagnosed influenza over...
9399548 - Reliability of mycobacteria growth indicator tube for testing susceptibility of mycobac...
11497538 - Strategies to decrease tuberculosis in us homeless populations: a computer simulation m...
10951598 - Litomosoides sigmodontis in mice: reappraisal of an old model for filarial research.
7795768 - Mumps outbreak in a highly vaccinated school population. evidence for large-scale vacci...
Publication Detail:
Type:  Congresses    
Journal Detail:
Title:  Tuberculosis (Edinburgh, Scotland)     Volume:  81     ISSN:  1472-9792     ISO Abbreviation:  Tuberculosis (Edinb)     Publication Date:  2001  
Date Detail:
Created Date:  2002-01-21     Completed Date:  2002-03-12     Revised Date:  2009-04-22    
Medline Journal Info:
Nlm Unique ID:  100971555     Medline TA:  Tuberculosis (Edinb)     Country:  England    
Other Details:
Languages:  eng     Pagination:  365-8     Citation Subset:  IM    
Copyright Information:
Copyright 2001 Harcourt Publishers Ltd.
Affiliation:
Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA. brennan@cber.fda.gov
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
BCG Vaccine*
Clinical Trials as Topic
Drug Evaluation, Preclinical / methods
Humans
Interinstitutional Relations
Research*
Tuberculosis / prevention & control*
Chemical
Reg. No./Substance:
0/BCG Vaccine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Use of the mycobacteriophage L5 excisionase in Mycobacterium tuberculosis to demonstrate gene essent...
Next Document:  Inhibition of doxorubicin chronic toxicity in catalase-overexpressing transgenic mouse hearts.